Transaction DateRecipientSharesTypePriceValue
2nd October 2020Mara G. Aspinall2,500Open or private sale$52.48$131,200.00
25th September 2020James A Datin1,492Grant/award etc.$10.89$16,247.88
25th September 2020James A Datin408Payment by withholding$10.89$4,443.12
9th September 2020Mara G. Aspinall2,500Open or private sale$50.48$126,200.00
4th September 2020Mara G. Aspinall2,500Open or private sale$48.48$121,200.00
28th August 2020Mara G. Aspinall2,500Open or private sale$46.48$116,200.00
23rd June 2020James A Datin455Payment by withholding$9.74$4,433.75
23rd June 2020James A Datin1,667Grant/award etc.$9.74$16,244.08
1st June 2020Lelio Marmora7,015Grant/award etc.$14.26$99,998.83
21st May 2020Mara G. Aspinall30,582Grant/award etc.$0.00
Ora Sure Technologies
Ora Sure Technologies logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 6/10.

OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic and collection devices and other technologies. It operates through the OSUR and DNAG segments. The OSUR segment develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices. The DNAG segment manufactures and sells specimen collection kits that are used for molecular testing.

Ticker: OSUR
Sector: Health Technology
Industry: Medical Specialties
SEC Central Index Key (CIK): 1116463
Employees: 472
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $174 M (129%)
Inventory, Net: $28 M (0%)
Other Assets, Current: $5 M (-10%)
Assets, Current: $318 M (41%)
Property, Plant and Equipment, Net: $34 M (11%)
Other Assets, Noncurrent: $3 M (-10%)
Assets: $421 M (0%)
Accounts Payable, Current: $9 M (-5%)
Liabilities, Current: $31 M (-6%)
Other Liabilities, Noncurrent: $3 M (-15%)
Liabilities: $39 M (-7%)
Common Stock, Shares, Issued: $71 Th (15%)
Additional Paid in Capital, Common Stock: $499 M (24%)
Retained Earnings (Accumulated Deficit): $100 M (21%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $17 M (42%)
Stockholders' Equity (Parent): $382 M (0%)
Liabilities and Equity: $421 M (20%)
Revenue: $29 M (0%)
Cost of Revenue: $12 M (-56%)
Gross Margin: $17 M (-48%)
Research and Development: $7 M (-44%)
Sales and Marketing: $10 M (-42%)
General and Administrative Expenses: $10 M (-49%)
Operating Income/Loss: $9 M (0%)
Provision for income taxes: $1 M (0%)
EPS (basic): $0.16 (0%)
EPS (diluted): $0.16 (0%)